Scarica l'app Stockscreener
5.31
3.91%
0.20
Pre-mercato:
5.39
0.08
+1.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$5.11
Aprire:
$5.09
Volume 24 ore:
2.77M
Relative Volume:
0.97
Capitalizzazione di mercato:
$554.06M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-3.2378
EPS:
-1.64
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
+2.71%
1M Prestazione:
+41.22%
6M Prestazione:
-3.28%
1 anno Prestazione:
-46.09%
Intervallo 1D:
$5.00
$5.46
Intervallo di 1 settimana:
$4.70
$5.46
Portata 52W:
$2.90
$10.11
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Confronta ALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
5.31 | 533.19M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Sell |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT) - Seeking Alpha
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down - geneonline.com
Durso succeeding Garg as Altimmune CEO - biocentury.com
Altimmune (NASDAQ:ALT) Stock Price Down 6.6%Time to Sell? - MarketBeat
Investors SueWallSt as Altimmune, Inc. Faces Securities Fraud Allegations - The National Law Review
Altimmune Announces CEO Transition and Succession Plan - The Globe and Mail
Key facts: Altimmune appoints Jerry Durso as CEO; pemvidutide trial data pending - TradingView
Gaithersburg drug developer Altimmune names new CEO as current chief readies exit - The Business Journals
Altimmune stock falls after CEO Garg announces 2026 departure By Investing.com - Investing.com Canada
Altimmune stock falls after CEO Garg announces 2026 departure - Investing.com
Altimmune, Inc. Announces CEO Changes - marketscreener.com
Altimmune CEO Vipin Garg to Step Down - marketscreener.com
Altimmune names Jerry Durso as new CEO effective January 2026 By Investing.com - Investing.com Canada
Altimmune (ALT) Announces CEO Transition Plan - GuruFocus
Altimmune falls as CEO Vipin Garg to step down - TradingView
Altimmune announces leadership change as CEO Vipin Garg steps down - Traders Union
Altimmune, Inc. Announces CEO Transition as Jerry Durso Succeeds Vipin Garg, Ph.D. - Quiver Quantitative
Altimmune Announces CEO Transition, Succession Plan - TradingView
Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT - MarketBeat
Altimmune Investors Drop Suit Over Liver Drug Trial, Stock Drop - Bloomberg Law News
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Altimmune (Nasdaq: ALT) to Present Chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - MSN
Altimmune Target of Unusually Large Options Trading (NASDAQ:ALT) - MarketBeat
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment - ts2.tech
Altimmune’s RECLAIM STUDY: A New Hope for Alcohol Use Disorder Treatment - MSN
Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - MSN
Net debt of Altimmune, Inc. – HAM:3G0 - TradingView
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment - MSN
Will Altimmune Inc. stock outperform international peersJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
While institutions invested in Altimmune, Inc. (NASDAQ:ALT) benefited from last week's 10% gain, individual investors stood to gain the most - simplywall.st
How Altimmune Inc. stock benefits from global expansion2025 Big Picture & Verified Entry Point Signals - newser.com
How strong is Altimmune Inc. stock revenue growthWeekly Trend Report & Accurate Intraday Trading Signals - newser.com
Transcript : Altimmune, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-20-2025 08 - MarketScreener
Altimmune at Jefferies Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com India
Will Altimmune Inc. stock reach all time highs in 2025July 2025 Big Picture & Smart Investment Allocation Tips - newser.com
Will Altimmune Inc. stock gain from government policies2025 Fundamental Recap & Low Risk Growth Stock Ideas - newser.com
Is Altimmune Inc. stock supported by strong fundamentals2025 Trade Ideas & Technical Confirmation Trade Alerts - newser.com
Using AI based signals to follow Altimmune Inc.Quarterly Risk Review & Free Weekly Watchlist of Top Performers - newser.com
What MACD and RSI say about Altimmune Inc.Sell Signal & Accurate Technical Buy Alerts - newser.com
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):